A multidisciplinary group (representing various professional bodies and supported by the Cystic Fibrosis Trust) has developed evidence-based guidelines for the performance of the sweat test in the UK. The guidelines cover patient information, subject suitability, sweat collection, sweat analysis, quality, interpretation of results, and responsibility for testing and training. The guidelines were produced following a detailed literature search by the process described by the Royal College of Paediatrics and Child Health (RCPCH), using the Scottish Intercollegiate Guidelines Network 1 (SIGN 1) criteria to grade the evidence. Recommendations are graded A, B, or C, depending on the level of evidence. The grade B recommendations (there were no grade A recommendations) were subsequently appraised and endorsed as part of the RCPCH process, according to Appraisal of Guidelines for Research and Evaluation in Europe (AGREE). The recommendations are summarized in tabular form representing the final version incorporating the comments from the appraisal process. Both the appraisal comments and the full evidence base can be found on www.rcpch.ac.uk/publications/clinical_docs.html. The full guidelines can also be found on
Introduction
The sweat test, a quantitative measurement of electrolytes in sweat, remains a key investigation in supporting the diagnosis of cystic ¢brosis (CF). Indications for sweat testing include: phenotype suggestive of CF, family history of CF, follow-up of some newborn screening tests, suspicion of an atypical CF phenotype.
In the majority of classical CF patients with typical features and identi¢ed mutations, the sweat test is diagnostic. In atypical CF where unusual CF transmembrane regulator (CFTR) mutations have been identi¢ed, the sweat test can be intermediate, but is usually helpful in supporting a diagnosis. 1, 2 The diagnosis of CF can remain uncertain in patients with suggestive clinical features or a consistently abnormal newborn immunoreactive trypsin screening result, an intermediate sweat test, and one or no identi¢ed mutations. Very rarely, the sweat test is normal in a patient with a genotype of CF. 3--5 The sweat test remains an important laboratory test to support the diagnosis of CF. It is of critical importance that sweat testing be carried out accurately with measurement of relevant analytes to allow the most accurate discrimination of normal, intermediate, and abnormal results. This is particularly relevant to tests carried out on patients whose clinical picture and mutation testing have yielded inconclusive results. Sweat testing is currently performed in approximately 180 laboratories across the UK. In most cases, a clinical chemistry department performs sweat collection and analysis.
A UK audit, with data collected in 1999, demonstrated wide variability in practice and standards. 6 Particular matters of concerns were lack of appropriate quality control for analytical methods, a substantial number of laboratories measuring sodium alone, variability in reference ranges, lack of audit, and sporadic reports of adverse patient events. These ¢ndings stimulated the UK National External Quality Assessment Scheme (UK NEQAS) via its Specialist Advisory Group for Paediatric Investigations to establish an external quality assessment scheme for sweat analysis, and highlighted the need for evidence-based guidelines for performance of the sweat test.
The guideline production process
A multidisciplinary group (representing various professional bodies and support from the Cystic Fibrosis Trust) ( Table 1) has developed evidence-based guidelines for the performance of the sweat test in the UK. This initiative arose via the Specialist Advisory Group for Paediatric Investigation of UK NEQAS. The guidelines cover patient information, subject suitability, sweat collection, sweat analysis, quality, interpretation of results, and responsibility for testing and training.
The guidelines were produced following a detailed literature search by the process described by the Royal College of Paediatrics and Child Health (RCPCH), 7 using the Scottish Intercollegiate Guidelines Network 1 (SIGN 1) 8 criteria to grade the evidence. Recommendations are graded A, B, or C, depending on the level of evidence ( Table 2 ). The grade B recommendations (there were no grade A level recommendations) were subsequently appraised and endorsed 9 as part of the RCPCH process, according to Appraisal of Guidelines for Research and Evaluation in Europe (AGREE). A subsequent review of the guidelines 10 by Dr Harry Baumer on behalf of the RCPCH highlights the key points and emphasizes the measurement of sweat chloride.
The recommendations summary, reproduced in Table 3 , is the ¢nal version incorporating the comments from the appraisal process. Both the appraisal comments and the full evidence base can be found on www.rcpch.ac.uk/publications/clinical_docs.html. The full guidelines can also be found on http://www. ukneqas.org.uk/guidelines.htm.
After publication of the guidelines -what next?
The summary recommendations are reproduced in this article ( Table 3 ) and have been disseminated via the following organizations: 
Association of Clinical Biochemists British Paediatric Respiratory Society British Thoracic Society Cystic Fibrosis Trust National External QualityAssurance Schemes Royal College of Pathologists

Sweat collection
The flexor surface of either forearm is the preferred site for sweat collection C Consideration may be given to other sites if both arms are eczematous, too small or otherwise unsuitable. Other sites used successfully include the upper arm, thigh, and back Great care must be taken at all stages of the procedure to avoid contamination (see example standard operating procedures [SOP]) C In response to a sweat test request, it is sufficient to carry out one sweat collection only Not graded * + (2) The power supply used must be battery powered and should include a safety cutout C Monitoring of the current must be carried out throughout iontophoresis where possible Wescor systems from model 3600 onwards have no ammeter but have an appropriate safety cutout system The power supply and electrodes must be regularly checked, maintained and records kept Electrical safety of all power supplies must be checked annually Electrodes should be of a suitable size and curvature to fit snugly on the patient's limb C They are most commonly made of copper or stainless steel Electrodes should be firmly secured in position to the electrolyte support pads or gels using straps that are adjustable to fit the patient (e.g. Velcro or rubber). Electrodes must be regularly cleaned, inspected, and discarded if they show pitting or irregularities 
Quality
Sweat which has been subject to evaporation and/or contamination must not be measured C The analytical range of the methods used must cover the concentration ranges found in normals and subjects with CF C The analytical methods must be fully documented as SOP to comply with CPA (or equivalent standard). The SOP must include the analytical method(s), quality control procedures, reporting, interpretation, and safety aspects Pending further data on conductivity measurements, a value below 60 mmol/L (NaCl equivalents) is unlikely to be associated with CF. It is hoped that local multidisciplinary teams performing sweat collection and analysis will assess the need for any changes in their sweat test procedure and set up an appropriate audit process as suggested in the guidelines.
The key points for audit at local level are: Prospective work to audit changes in practice is required to assess the impact of the guidelines. New evidence must continue to be collected in order to undertake review and produce an update at an early date.
In compiling the evidence base for the guidelines, it was apparent that much of the local and regional data available had not been published in a peer-reviewed journal, but were nevertheless vitally important to assess the current status of UK sweat test performance. Reliance on published data alone would have resulted in a skewed and out-of-date picture, dominated by the population tested by the CF regional centres, which is not where the majority of children have their initial sweat tests performed. Readers with new evidence (published/unpublished) are strongly encouraged to contact the authors with their data, so that it could be incorporated into the review process. It is hoped that this publication will stimulate the collection of data on a local basis, which can then be compiled for the new evidence base.
Discussion
Sweat testing remains a key investigation in the diagnosis of CF. These guidelines provide the ¢rst evidence Sweat collection conditions should be adhered to, in particular the iontophoresis time and the collection duration.
Collected sweat (either ¢lter paper or liquid from Macroduct) can be stored, thereby allowing geographical separation of collection and analysis.
Sweat collections below a minimum sweat rate
should not be analysed, and collections should not be pooled.
Sweat chloride must be measured to support a diagnosis of CF. There is good evidence that chloride is a better discriminator than sodium. Sodium alone should not be used. Sweat chloride below 40 mmol/L is normal and there is a low probability of CF. Sweat chloride above 60 mmol/L supports the diagnosis of CF.
There must be a standard operating procedure (SOP) for both collection and analysis with appropriate quality control and external quality assurance (the guidelines include a sample SOP and patient lea£et).
The guidelines raised several issues.
Transport of sweat samples
Some centres that carry out between 10 and 50 sweat tests per annum meet the guidelines for collection but not for analysis. Such units may be geographically remote from the nearest centre, whose annual workload exceeds 50. A potential way forward for these units is to carry out sweat collection locally, according to the guidelines, and transport the collected sweat to the larger workload centre for analysis. Division of the collection and analysis components of the sweat test allows the quality of both to be optimized, while importantly maintaining equity of access to the test for children and their families.
Availability of pilocarpine
The guidelines described pilocarpine used for iontophoresis as an unlicensed, relevant medical product ('special') that should be obtained from a 'specials' licensed manufacturer. The statement that laboratories should not manufacture electrolyte solutions for iontophoresis in house led to a signi¢cant change in practice in a number of UK laboratories, and may have contributed to a short-term supply problem from the small number of 'specials' manufacturers in the UK.
Analytes measured
The place of chloride in the diagnosis of CF is well established, and the guidelines state that chloride must be measured. It is the analyte most commonly measured by laboratories participating in the UK NEQAS Sweat Testing Surveys. Sodium is measured by fewer laboratories, and conductivity by a smaller but steadily increasing number. The UK NEQAS data on analyte performance demonstrate that measurement of conductivity has a much better precision than chloride. However, the question of whether this is su⁄cient to outweigh the theoretical disadvantages of its measurement, particularly in patients with intermediate sweat chloride who may have atypical CF, requires a greater body of data than was available at the time the guidelines were written. Analysis of paired conductivity and chloride measurements in patient samples with intermediate or abnormal results is an achievable consequence of the transportability of sweat collections. Such data collection, targeted to those results that cause di⁄culty in interpretation, will be crucial in providing an evidence-based answer to the usefulness of conductivity relative to chloride results in real patients, especially if also coupled to CFTR mutation analysis.
Methodology
The guidelines stated that the Orion electrode was an unsuitable method that should not be used. Following publication of the guidelines, a substantial number of laboratories abandoned this method, often coinciding with the retirement of a single highly experienced sta¡ member who had been responsible for its use. More recently, non-availability of spares and service for the Orion electrode led to its ongoing use by a vanishingly small number of laboratories. Data are continuing to be collected by UK NEQAS on the relative performance of the remaining chloride methods used. The outcome of this study will inform decisions about future choices. An operational issue for many centres is funding the replacement of equipment that is used solely for a small number of sweat chlorides.
Internal quality control of the procedure
The quality of the whole procedure can only be assessed by retrospective audit. Quality control, where the results inform the decision to release the patient's test result, is limited to sweat electrolyte analysis. It is this part of the procedure that is also targeted by the UK NEQAS. At the time of the guideline preparation, laboratories either prepared internal quality control material inhouse, or used commercial materials intended for use with urine or plasma samples, with concentrations that were not necessarily appropriate for sweat. A commercial, Conformite Ł Europe Ł ene (CE) marked, three-level sweat internal control is now available (Biostat) with quoted values for chloride, sodium, conductivity, potassium, and osmolality. The values broadly correspond to normal, intermediate and abnormal; however chloride has one normal and two abnormal concentrations.
Terminology used in interpretation
The guidelines recommend use of the term intermediate, rather than the previously common'equivocal'. This recognizes the existence of a spectrum of mutations in CFTR, leading to CF of varying severity, including atypical forms that consistently result in sweat chloride results that fall into this region. Such results are not equivocal, but re£ect an incomplete defect in chloride channel function in such cases. However, it is undoubtedly the case that a much larger number of patients have an initial sweat test result that falls into the intermediate region as a result of faulty sweat collection and/or analytical inaccuracy or imprecision. On repeat sweat testing, these patients have results that fall into the normal range. Audit of outcomes in patients with intermediate results must take this group of results into account.
Implications of the guidelines
The recommendation for minimum workload is based on unpublished UK NEQAS data, which showed that two or more errors had not occurred to date in those laboratories performing more than 100 sweat tests per annum, whereas 50% of the laboratories making two or more errors performed only 50 or less sweat analyses per year. UK NEQAS data also suggest that a substantial number of laboratories/units perform fewer than 50 sweat test analyses per year. Therefore, although it is emphasized that the guidelines are only recommendations, laboratories/units who perform less than 50 analyses a year should satisfy themselves of their quality before making a decision on how best to provide sweat testing.
The roll-out of newborn screening for CF across the UK has already impacted on the use of the sweat test. Unpublished data from Scotland, where newborn screening began in 2003, demonstrated a marked fall in the total number of sweat tests performed during the ¢rst year after screening implementation, along with an increased demand for sweat tests on babies at 3--4 weeks of age, following on from the newborn screen. The reduction in numbers has already resulted in increased division of collection and analysis sites, with transport of sweat for analysis.
The RCPCH recommended that the guidelines should be reviewed at an early date. The authors are aware that the practice of sweat testing within the UK has already changed markedly since evidence collection for the ¢rst edition was completed in 2001. These changes were driven in part by publication of the guidelines, but were also the result of:
Changed population being referred for sweat tests as newborn screening for CF using immunoreactive trypsin and mutation screening is rolled out across the UK.
Changes in laboratory sta⁄ng and analytical systems.
Laboratory rationalization and formation of area networks with common equipment provision and standard operating protocols.
Manufacturer's concerns about CE marking, along with the increasing age of some widely used types of equipment, leading to non-availability of parts and service for some older apparatus.
Laboratories' concerns about CE marking leading to a re-consideration of in-house versus commercial methodology.
Readers are strongly encouraged to critically review their sweat-testing practice, carry out local audit and report the results, either by submission to a peerreviewed journal or to an audit database (e.g. RCPath), or directly to the authors of this article. Only by completing this audit cycle can the next revision of the guidelines access a full and up-to-date evidence base and thus take forward the practice of sweat testing in the UK to re£ect the changing demands for this diagnostic procedure.
